LEGN - CIK 0001801198
Legend Biotech Corp trades as LEGN and has a market capitalization of $5.04 B, making it the #1378 largest US-listed company by market value. This page tracks Legend Biotech Corp through 343 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| 6-K | - | 2026-05-21 |
| 6-K | - | 2026-05-12 |
| 6-K | - | 2026-04-14 |
| Insider trade | 4 | 2026-03-27 |
| Insider sale notice | 144 | 2026-03-26 |
| Insider sale notice | 144 | 2026-03-26 |
| New insider ownership | 3 | 2026-03-18 |
| New insider ownership | 3 | 2026-03-18 |
Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million
Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio
During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively
The largest companies sharing Legend Biotech Corp's SEC industry classification (pharmaceutical preparations).
Legend Biotech Corp (LEGN) has a market capitalization of $5.04 B as of 2026-05-29, ranking #1378 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.